Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3819640 | 0.87 | MAPK14 (0.42) | MAPK14MAPK11 | |
| SCHEMBL3822000 | 0.86 | MAPK14 (0.45) | MAPK14MAPK11 | |
| SCHEMBL13763208 | 0.76 | MAPK14 (0.46) | MAPK14MAPK11 | |
| SCHEMBL4015729 | 0.72 | HSPB1 (0.38) | MAPK14 | |
| SCHEMBL3818948 | 0.72 | MAPK14 (0.48) | MAPK14MAPK11 | |
| SCHEMBL3876871 | 0.69 | MAPK14 (0.81) | MAPK14MAPK11 | |
| SCHEMBL3867906 | 0.68 | MAPK14 (0.46) | MAPK14MAPK11 | |
| SCHEMBL13769506 | 0.68 | DGAT2 (0.41) | MAPK14 | |
| SCHEMBL4017442 | 0.66 | MAPK14 (0.44) | MAPK14MAPK11 | |
| SCHEMBL15999455 | 0.66 | ELANE (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091952-A1 | PYRAZOLO Ý3, 4 -D¨PYRIMIDINE P38 MAP KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-08-26 | — | — | EP | disclosed |
| US-7563800-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563800-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | disclosed |
| WO-2008074676-A1 | PYRAZOLO [3, 4 -D] PYRIMIDINE P38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074676-A1 | PYRAZOLO [3, 4 -D] PYRIMIDINE P38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146590-A1 | P38 map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146590-A1 | P38 map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146590-A1 | P38 map kinase inhibitors and methods for using the same | MAPK1, MAP3K1, MAP3K7 | MAPK14 33/4885MAPK11 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.